Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENAL: Etanercept for Preventing Kidney Dysfunction After Lung Transplant
NCT05950724Phase 1Enrolling by invitation
- Sponsor
- Northwestern University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of etanercept in Kidney disease and primary graft dysfunction (PGD) (2 arms), sponsored by Northwestern University. Primary endpoints: Occurrence of kidney dysfunction immediately after lung transplant at 0 days, Occurrence of kidney dysfunction post-operatively within 1 week after lung transplant and 1 more. Started Sep 2023; status: enrolling by invitation.
02
Drugs
etanercept
03
Conditions
Kidney diseaseprimary graft dysfunction (PGD)
Beyond the preview
Go deeper on NCT05950724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05950724.